#151450

JIM3 Cell Line

Cat. #151450

JIM3 Cell Line

Cat. #: 151450

Sub-type: Primary

Unit size: 1x10^6 cells / vial

Organism: Human

Tissue: Blood

Disease: Cancer

Model: Tumour line

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: M.S. Hamilton

Institute: University of Birmingham

Tool Details
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: JIM3 Cell Line
  • Cancer: Blood cancer
  • Cancers detailed: Human multiple myeloma
  • Research fields: Cancer;Drug development;Genetics
  • Tool sub type: Primary
  • Organism: Human
  • Gender: Female
  • Tissue: Blood
  • Disease: Cancer
  • Model: Tumour line
  • Conditional: Yes
  • Description: JIM3 is a multiple myeloma cell line established from plasma myeloma cells derived from pleural fluid of an advanced multiple myeloma patient (Hamilton et al., 1991). JIM3 carries compound mutations in KRAS (G12D heterozygous) and TP53 (R273C homozygous) (Moreaux et al., 2011). The cell line exhibits deficient DNA mismatch repair capacity with reduced G/T repair activity, and microsatellite instability (Velangi et al 2004). JIM3 displays a plasma cell phenotype and is a model for studying compound genetic lesions, DNA repair deficiency and genomic instability in multiple myeloma research.
  • Production details: Derived from plasma myeloma cells from pleural fluid of advanced multiple myeloma female patient.
  • Cellosaurus id: CVCL_2533

Handling

  • Format: Frozen
  • Growth medium: Dexter culture medium, consisting of Fischer's medium + 20% FCS +10-7 M hydrocortisone sodium succinate. Seed at 2-9 x 10 5 cells/cm3 5% CO2; 37 °C
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice

References

  • Hamilton M.S. et al. 1991. Leukemia. 5:768-771. PMID: 1943229
  • Bergsagel P.L. et al. 1996. Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936. PMID: 8943038
  • Sakai A. et al. 1998. Blood. 92:3410-3415. PMID: 9787181
  • Kuipers J. et al. 1999. Cancer Genet. Cytogenet. 109:99-107. PMID: 10087940
  • Drexler H.G. et al. 2000. Leuk. Res. 24:681-703. PMID: 10936422
  • Chesi M. et al. 2001. Blood. 97:729-736. PMID: 11157491
  • Velangi et al. 2004. Carcinogenesis. 25(10):1795-803. PMID: 15142887
  • Bataille F.-R. et al. 2006. Haematologica. 91:1234-1240. PMID: 16956823
  • Keats J.J. et al. 2007. Cancer Cell. 12:131-144. PMID: 17692805
  • Dib A. et al. 2008. J. Natl. Cancer Inst. Monogr. 39:25-31. PMID: 18647998
  • Leone et al. 2008. Clin Cancer Res. 14(19):6033-41. PMID: 18829482
  • Moreaux J. et al. 2011. Haematologica. 96:574-582. PMID: 21173094
  • Maiga S. et al. 2015. Cytometry A. 87:285-288. PMID: 25688540
  • Tessoulin B. et al. 2018. J. Hematol. Oncol. 11:137.1-137.13. PMID: 30545397
  • Sarin V. et al. 2020. Leukemia. 34:2754-2765. PMID: 32123307.